-
Something wrong with this record ?
Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications
B. Ostadal, P. Ostadal,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 1968 to 1 year ago
PubMed Central
from 1968 to 2020
Europe PubMed Central
from 1968 to 1 year ago
Medline Complete (EBSCOhost)
from 2002-01-01 to 1 year ago
Wiley Free Content
from 1997 to 1 year ago
PubMed
23750471
DOI
10.1111/bph.12270
Knihovny.cz E-resources
- MeSH
- Acute Coronary Syndrome drug therapy metabolism physiopathology MeSH
- Androgens metabolism MeSH
- Estrogens metabolism MeSH
- Myocardial Ischemia drug therapy metabolism physiopathology MeSH
- Cardiovascular Agents therapeutic use MeSH
- Humans MeSH
- Evidence-Based Medicine * MeSH
- Myocardium metabolism MeSH
- Disease Susceptibility MeSH
- Sex Characteristics MeSH
- Myocardial Reperfusion Injury prevention & control MeSH
- Heart drug effects physiopathology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Ischaemic heart disease (IHD) is the most frequent cause of mortality among men and women. Many epidemiological studies have demonstrated that premenopausal women have a reduced risk for IHD compared with their male counterparts. The incidence of IHD in women increases after menopause, suggesting that IHD is related to declining oestrogen levels. Experimental observations have confirmed the results of epidemiological studies investigating sex-specific differences in cardiac tolerance to ischaemia. Female sex appears also to favourably influence cardiac remodelling after ischaemia/reperfusion injury. Furthermore, sex-related differences in ischaemic tolerance of the adult myocardium can be influenced by interventions during the early phases of ontogenetic development. Detailed mechanisms of these sex-related differences remain unknown; however, they involve the genomic and non-genomic effects of sex steroid hormones, particularly the oestrogens, which have been the most extensively studied. Although the protective effects of oestrogen have many potential therapeutic implications, clinical trials have shown that oestrogen replacement in postmenopausal women may actually increase the incidence of IHD. The results of these trials have illustrated the complexity underlying the mechanisms involved in sex-related differences in cardiac tolerance to ischaemia. Sex-related differences in cardiac sensitivity to ischaemia/reperfusion injury may also influence therapeutic strategies in women with acute coronary syndrome. Women undergo coronary intervention less frequently and a lower proportion of women receive evidence-based therapy compared with men. Although our understanding of this important topic has increased in recent years, there is an urgent need for intensive experimental and clinical research to develop female-specific therapeutic strategies. Only then we will be able to offer patients better evidence-based treatment, a better quality of life and lower mortality.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008614
- 003
- CZ-PrNML
- 005
- 20150313102044.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bph.12270 $2 doi
- 035 __
- $a (PubMed)23750471
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ostadal, B $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications / $c B. Ostadal, P. Ostadal,
- 520 9_
- $a Ischaemic heart disease (IHD) is the most frequent cause of mortality among men and women. Many epidemiological studies have demonstrated that premenopausal women have a reduced risk for IHD compared with their male counterparts. The incidence of IHD in women increases after menopause, suggesting that IHD is related to declining oestrogen levels. Experimental observations have confirmed the results of epidemiological studies investigating sex-specific differences in cardiac tolerance to ischaemia. Female sex appears also to favourably influence cardiac remodelling after ischaemia/reperfusion injury. Furthermore, sex-related differences in ischaemic tolerance of the adult myocardium can be influenced by interventions during the early phases of ontogenetic development. Detailed mechanisms of these sex-related differences remain unknown; however, they involve the genomic and non-genomic effects of sex steroid hormones, particularly the oestrogens, which have been the most extensively studied. Although the protective effects of oestrogen have many potential therapeutic implications, clinical trials have shown that oestrogen replacement in postmenopausal women may actually increase the incidence of IHD. The results of these trials have illustrated the complexity underlying the mechanisms involved in sex-related differences in cardiac tolerance to ischaemia. Sex-related differences in cardiac sensitivity to ischaemia/reperfusion injury may also influence therapeutic strategies in women with acute coronary syndrome. Women undergo coronary intervention less frequently and a lower proportion of women receive evidence-based therapy compared with men. Although our understanding of this important topic has increased in recent years, there is an urgent need for intensive experimental and clinical research to develop female-specific therapeutic strategies. Only then we will be able to offer patients better evidence-based treatment, a better quality of life and lower mortality.
- 650 _2
- $a akutní koronární syndrom $x farmakoterapie $x metabolismus $x patofyziologie $7 D054058
- 650 _2
- $a androgeny $x metabolismus $7 D000728
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kardiovaskulární látky $x terapeutické užití $7 D002317
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a estrogeny $x metabolismus $7 D004967
- 650 12
- $a medicína založená na důkazech $7 D019317
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdce $x účinky léků $x patofyziologie $7 D006321
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ischemická choroba srdeční $x farmakoterapie $x metabolismus $x patofyziologie $7 D017202
- 650 _2
- $a reperfuzní poškození myokardu $x prevence a kontrola $7 D015428
- 650 _2
- $a myokard $x metabolismus $7 D009206
- 650 _2
- $a pohlavní dimorfismus $7 D012727
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ostadal, P
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 171, č. 3 (2014), s. 541-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23750471 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150313102323 $b ABA008
- 999 __
- $a ok $b bmc $g 1065887 $s 891414
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 171 $c 3 $d 541-54 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- LZP __
- $a Pubmed-20150306